BROOKSBrooks Laboratories Limited
Pharma · Drug Manufacturers - Specialty & Generic · NSE · as of 2026-10-28 (delayed ~30 min in market hours)
Brooks Laboratories Limited operates as a pharmaceutical manufacturer in India and internationally. It operates in two segments, Manufacturing and Trading. The company offers liquid injection ampoules and vials, dry powder injection vials, lyophilized injections, eye/ear drops, and nasal drops; and B-Lactam and cephalosporin tablets, dry powder syrups, and injections. It is also involved in loan-licensing business relating to pharmaceutical products, ingredients, and intermediaries; and trading in pharmaceutical products, ingredients, and intermediaries. In addition, the company offers oncology products and hormonal injections; and formulations for therapeutic areas comprising antibiotic, pain management, controlled drugs. It exports its products to Afghanistan, Yemen, Kosovo, Bolivia, Guatemala, Turkmenistan, Nigeria, Lebanon, Mauritius, Sudan, Madagascar, the Democratic Republic of Congo, Angola, Mozambique, Latin America, and Africa. Brooks Laboratories Limited was incorporated in 2002 and is based in Mumbai, India.
Price & Volume
Loading chart…
Key Ratios
“—” means the figure isn't meaningful or isn't published for this company: ROE and Debt/Equity are undefined when shareholder equity is negative (check P/B — negative means negative equity), and DII/MF holding splits aren't provided by our current data source.
Active Pattern Signals
None of the 16 pattern scanners currently detects a setup on BROOKS — signals appear here automatically when one forms (checked on every data refresh). The Trade Plan on the right always provides stop-loss and target levels regardless.
Why avoid
- • Risk gate: safety score is only 24/100 — volatility, drawdown or liquidity is too poor for a buy call, whatever the chart says
- • Revenue growth: -10.0% YoY
- • ROCE: 4.2%
- • MACD: bearish
- • Price vs EMA21: below
Bull case
- • Profit growth: 346.5% YoY
- • ROE: 20.0%
- • Debt/Equity: 0.07
- • 3-month vs NIFTY: +5.4% relative
Bear case
- • Revenue growth: -10.0% YoY
- • ROCE: 4.2%
- • MACD: bearish
- • Price vs EMA21: below
Key risks
- • Elevated volatility / drawdown profile — size positions accordingly
- • Revenue growth: -10.0% YoY
- • ROCE: 4.2%
Algorithmic analysis for research only — not SEBI-registered investment advice.
Trade Plan
Stop = 20-day support with a 2.5×ATR risk cap (ATR ₹4.78). Levels recompute on every data refresh. Position sizing and execution are yours — this is analysis, not advice.